Oracle Corp (NYSE: ORCL) shares rose to $150.85, recovering from a July low of $114.43, as investors await the company’s fiscal first-quarter earnings report scheduled for September 8, 2026.

The stock has underperformed the broader market this year, slipping by over 23.6% since January despite the Nasdaq 100 and S&P 500 reaching record highs. This divergence highlights market concern over Oracle’s aggressive capital expenditure strategy, even as its underlying business metrics show strength.

Earnings Estimates and Growth Outlook

Analysts project significant year-over-year growth for the upcoming quarter. Benzinga data indicates expectations for revenue to jump 28% to $19 billion. This follows a fourth-quarter revenue figure of $19.2 billion, which represented a 19% increase and contributed to an annual revenue total of $67.4 billion.

The current price-to-earnings ratio stands at 24.4x based on prior estimates, though forward P/E ratios have dropped to 18.7x, lower than the sector median of 22.7x. Analysts now expect annual revenue to reach $90 billion, followed by $130 billion in the subsequent financial year.

Capital Expenditure and Debt Concerns

Investor attention remains fixed on Oracle’s aggressive expansion of artificial intelligence infrastructure. The company spent $48 billion in capital expenditures last fiscal year and plans to nearly double that to $70 billion in FY27. These funds are being raised through a mix of equity and debt, with some debt rated a notch above junk status.

Previously cited guidance had suggested capital expenditures of up to $95 billion in fiscal 2027, alongside future data center lease commitments of roughly $260 billion. The discrepancy in figures reflects evolving guidance or specific project phases, intensifying scrutiny regarding cash flow impacts. Operational updates regarding Project Jupiter noted a six-month delay for a New Mexico gas pipeline serving the site, pushing completion to February 2027, though the data center project itself remains on schedule.

Remaining Performance Obligations

Oracle’s remaining performance obligations (RPO) jumped by over $85 billion in the quarter to $638 billion. This substantial backlog provides visibility into future revenue streams, supporting the bullish outlook among several analysts.

Market Sentiment and Analyst Views

Divergent views on Oracle’s valuation persist. Michael Burry disclosed an increased short position around $152, arguing that the AI infrastructure boom could result in excess computing capacity. Conversely, analyst consensus maintains a Buy rating with an average price forecast of $258.50.

Recent analyst actions include:

• Citigroup: Maintained Buy rating and raised forecast to $330.00.
• UBS: Maintained Buy rating but lowered forecast to $245.00.
• Bernstein: Raised forecast to $325.00 with an Outperform rating.
• Barclays: Hiked forecast to $250.00.
• CLSA: Initiated coverage with a Hold rating and a $145.00 forecast.

Technical Setup and Price Action

Oracle’s stock has climbed back above both its 20-day and 50-day moving averages. It sits more than 2% above the 20-day mark of $144.65 and about 3.5% above the 50-day level of $142.90. The stock has also jumped above the crucial resistance level of $133.95, its lowest swing in February and June this year.

However, the longer-term trend remains shakier, with shares running about 10.2% below their 100-day average of $164.41 and around 14% under their 200-day average of $171.54. A death cross from January keeps the longer-term trend tilted bearish. Momentum readings offer a clearer signal than price alone, with the relative strength index sitting at 52.68 in neutral territory.

ETF Exposure

Oracle carries significant weight in several technology-focused exchange-traded funds:

• iShares Expanded Tech-Software Sector ETF (IGV): 5.87% weight
• FT Vest Technology Dividend Target Income ETF (TDVI): 5.30% weight
• First Trust NASDAQ Technology Dividend Index Fund (TDIV): 5.28% weight

Oracle Corp (NYSE: ORCL) shares rose 1.51% to $144.95 on Wednesday, outperforming a weak technology sector that fell approximately 0.8%. The stock’s relative strength came as investors reacted to the company’s expansion into healthcare artificial intelligence and maintained optimism ahead of its next earnings report.

Healthcare AI Expansion

Oracle expanded its Oracle Health Clinical AI Agent with new capabilities for clinical documentation, coding, and chart review. Available in the U.S., the updated agent suggests professional fee charge codes based on patient visits, which clinicians must review and approve before submission.

The tool also reviews electronic health records to summarize patient information, including medical history, lab results, and medications. Additionally, Oracle introduced clinician-controlled dictation, which transcribes speech directly into clinical documentation for editing.

These features build on previously announced AI tools for automated order creation. Oracle stated that its AI-powered note generation has saved physicians more than 400,000 hours across U.S. health organizations since its launch nearly two years ago.

Technical Positioning

Despite the daily gain, Oracle’s longer-term technical trend remains bearish. The stock traded 4.4% above its 20-day simple moving average (SMA) of $138.14, but remained 2.4% below its 50-day SMA of $147.81 and more than 12% below its 100-day SMA of $164.35.

A death cross formed in January, with the 50-day SMA remaining below the 200-day SMA. The relative strength index stood at 49.45, indicating neutral momentum where neither buyers nor sellers have firm control. Resistance sits near $149, close to the 50-day SMA, while support is around $135.

Earnings Outlook And Analyst Views

Analysts expect Oracle to report earnings of $1.67 per share for the quarter ending in September, up from $1.47 a year earlier. Revenue is forecast to reach $19.13 billion, compared with $14.93 billion in the prior-year period. The next earnings report is estimated for Sept. 8.

The stock carries a Buy consensus rating with an average price forecast of $258.50. Recent analyst actions include:

• UBS maintained a Buy rating on Aug. 6 but lowered its price forecast to $245.
• CLSA initiated coverage with a Hold rating and $145 price forecast on July 20.
• Bernstein maintained an Outperform rating and raised its price forecast to $325 on June 11.

Market Context And ETF Exposure

The broader market was mixed, with seven sectors advancing and an advance-decline ratio of 1.8. Health care led gains with a 2.99% increase, followed by materials at 1.80%. The Nasdaq fell 0.10%, while the S&P 500 gained 0.29%.

Oracle holds significant weightings in several technology-focused exchange-traded funds:

As a major holding, Oracle’s performance can be influenced by inflows and outflows from these funds. According to Benzinga Edge rankings, Oracle scores strongly on growth (95.91) but remains weak on momentum (6.43) and value (19.07).

What the Numbers Show

Oracle’s strong growth score (95.91) contrasts sharply with its low momentum score (6.43), reflecting a divergence between fundamental earnings expectations and current technical price action. While analysts project revenue growth from $14.93 billion to $19.13 billion, the stock remains below key moving averages, suggesting that recent gains are driven more by sector rotation and specific product news than by a reversal in broader technical trends.